As steroid hormones are central regulators of systemic metabolism, ERs and ARs increase glucose tolerance and restrain visceral fat accumulation, and, thus, in postmenopausal women with reduced ERα signalling and with individuals with aromatase deficiency having compromised AR to ER conversion, tend to have increased adiposity, which is a risk factor for cancer development [8]. Here, CYP19A1 is linked to cancer.